Akero Therapeutics Statistics
Share Statistics
Akero Therapeutics has 69.80M shares outstanding. The number of shares has increased by 1.24% in one year.
| Shares Outstanding | 69.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.53% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 58.30M |
| Failed to Deliver (FTD) Shares | 1.47K |
| FTD / Avg. Volume | 0.25% |
Short Selling Information
The latest short interest is 3.30M, so 4.73% of the outstanding shares have been sold short.
| Short Interest | 3.30M |
| Short % of Shares Out | 4.73% |
| Short % of Float | 5.66% |
| Short Ratio (days to cover) | 5.51 |
Valuation Ratios
The PE ratio is -8.09 and the forward PE ratio is -7.62.
| PE Ratio | -8.09 |
| Forward PE | -7.62 |
| PS Ratio | 0 |
| Forward PS | 56.1 |
| PB Ratio | 2.29 |
| P/FCF Ratio | -8.44 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Akero Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 29.27, with a Debt / Equity ratio of 0.05.
| Current Ratio | 29.27 |
| Quick Ratio | 29.27 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.46 |
| Cash Flow / Debt | -5.82 |
| Interest Coverage | -55.78 |
Financial Efficiency
Return on equity (ROE) is -0.28% and return on capital (ROIC) is -30.78%.
| Return on Equity (ROE) | -0.28% |
| Return on Assets (ROA) | -0.26% |
| Return on Capital (ROIC) | -30.78% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.53M |
| Employee Count | 60 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 23.56% in the last 52 weeks. The beta is -0.26, so Akero Therapeutics 's price volatility has been lower than the market average.
| Beta | -0.26 |
| 52-Week Price Change | 23.56% |
| 50-Day Moving Average | 30.5 |
| 200-Day Moving Average | 25.93 |
| Relative Strength Index (RSI) | 42.96 |
| Average Volume (20 Days) | 595.88K |
Income Statement
| Revenue | n/a |
| Gross Profit | -29.00K |
| Operating Income | -172.87M |
| Net Income | -151.76M |
| EBITDA | -148.63M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.89 |
Balance Sheet
The company has 234.21M in cash and 26.30M in debt, giving a net cash position of 207.90M.
| Cash & Cash Equivalents | 234.21M |
| Total Debt | 26.30M |
| Net Cash | 207.90M |
| Retained Earnings | -574.10M |
| Total Assets | 817.55M |
| Working Capital | 703.60M |
Cash Flow
In the last 12 months, operating cash flow was -145.37M and capital expenditures 0, giving a free cash flow of -145.37M.
| Operating Cash Flow | -145.37M |
| Capital Expenditures | 0 |
| Free Cash Flow | -145.37M |
| FCF Per Share | -2.77 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AKRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10.24% |
| FCF Yield | -7.38% |
Analyst Forecast
The average price target for AKRO is $46, which is 63% higher than the current price. The consensus rating is "Buy".
| Price Target | $46 |
| Price Target Difference | 63% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 13.9 |
| Piotroski F-Score | 2 |